We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




LINGO-1 May Lead to MS Therapy

By Biotechdaily staff writers
Posted on 15 Jun 2005
Scientists have identified a molecule in the central nervous system (CNS) called LINGO-1 that plays a role in nerve repair and may lead to pathways for treating multiple sclerosis (MS) and other demyelinating diseases.

Research findings indicate that LINGO-1 is a molecular switch that controls the ability of CNS cells to myelinate. More...
Scientists discovered that LINGO-1 normally acts to prevent myelination and its normal function could be blocked in laboratory tissue culture. They were able to generate large quantities of myelin by blocking LINGO-1 and, for the first time ever in a laboratory, were able to wrap it correctly around nerves.

"We believe that the LINGO-1 research has significantly added to the body of knowledge about nerve repair in multiple sclerosis and other demyelinating diseases,” observed John Richert, M.D., vice president, clinical and research programs, National Multiple Sclerosis Society. "We hope it will one day lead to improved treatments for MS and the repair of the central nervous system.”

MS is a chronic disease of the CNS in which the body's own immune cells break down myelin, a fatty substance that surrounds nerve cells like the insulation around a wire. Without myelin, nerves lose the ability to conduct impulses and eventually die. In MS patients, the CNS cells that wrap nerves in myelin fail to restore the missing myelin sheath following an immune system attack.

LINGO-1 was discovered by scientists at Biogen Idec (Cambridge, MA, USA). "Although it is still uncertain whether we can transform these observations into a therapy, our research team has provided the first indications of a new pathway that may enable us to repair the nerve damage found in patients afflicted by MS and other serious demyelinating diseases,” noted Michael Gilman, Ph.D., executive vice president, research, Biogen Idec. The findings were reported in the June 2005 issue of Nature Neuroscience.




Related Links:
Biogen

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.